BCTXW (NASDAQ) is a cross-listing of BCTX (NASDAQ). Showing primary listing data.
BCTX
BriaCell Therapeutics Corp.
1W: -13.9%
1M: -0.3%
3M: -48.5%
YTD: -45.8%
1Y: -90.5%
3Y: -99.6%
5Y: -91.5%
$3.89
-0.16 (-3.95%)
After Hours: $4.11 (+0.22, +5.66%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$7.3M
52W Range3.6-98.2
Volume137,743
Avg Volume500,505
Beta1.80
Dividend—
Analyst Ratings
Company Info
CEOWilliam V. Williams
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2012-03-14
Websitebriacell.com
Bellevue Centre
West Vancouver, BC V7T 2X1
CA
West Vancouver, BC V7T 2X1
CA
604 921 1810
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Latest News
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lustig Marc | P-Purchase | 902,935 | $2.21 | 2024-05-14 |
| Lustig Marc | P-Purchase | 902,935 | $2.11 | 2024-05-14 |
| Bondarenko Jamieson | P-Purchase | 28,000 | $4.58 | 2022-12-28 |
| Williams William V. | P-Purchase | 2,530 | $1.94 | 2022-12-23 |
| Bondarenko Jamieson | P-Purchase | 22,000 | $5.35 | 2022-12-20 |